OncLive TV

Matthew Wagar, MD, discusses the use of adjuvant immunotherapy in endometrial cancer and the importance of accurate staging in optimizing outcomes.

The MANIFEST-2 trial showed that pelabresib/ruxolitinib led to greater spleen volume reduction and improved anemia vs ruxolitinib alone in myelofibrosis

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

Ryan Sullivan, MD, discusses RP1 plus nivolumab in patients with advanced melanoma who progressed on prior anti–PD-1 therapy.

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.

Teresa Petrella, MD, MHSc, FRCPC, discusses considerations in selecting frontline therapy for patients with metastatic melanoma.

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

Elias Jabbour, MD, discusses data for bleximenib in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements or NPM1 mutations.

Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.

Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.

John Andrew Livingston, MD, MS, discusses responses with gemcitabine, docetaxel, and hydroxychloroquine in advanced, metastatic osteosarcoma.

Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Rona Yaeger, MD, details the efficacy of adagrasib/cetuximab in heavily pretreated patients with KRAS G12C–mutant mCRC.

Paolo A. Ascierto, MD, discusses findings from the SECOMBIT and DREAMseq trials and their implications for first-line treatment selection for patients with BRAF-mutant melanoma.

Caroline Robert, MD, PhD, discusses the role of adjuvant anti–PD-1 therapy in resected stage IIB/IIC melanoma based on findings from the KEYNOTE-716 and CheckMate 76K trials.

Charles B. Nguyen, MD, discusses the updated 2024 NCCN Guidelines and their effect on treatment decisions for non–clear cell RCC.

Yi Lin, MD, PhD, discuses cilta-cel vs standard of care in patients with lenalidomide-refractory multiple myeloma.

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab for adult patients with KRAS G12C–mutated metastatic colorectal cancer.

Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Timothy S. Fenske, MD, MS, details the rationale of a phase 3 trial assessing rituximab with or without ASCT in mantle cell lymphoma.

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses updated safety and efficacy data with daraxonrasib in KRAS-mutated pancreatic ductal adenocarcinoma.

Marwan G. Fakih, MD, discusses response rates with botensilimab plus balstilimab in patients with microsatellite-stable colorectal cancer.

Juan Pablo Alderuccio, MD, discusses the combination of loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma.

Tina Cascone, MD, PhD, discusses the efficacy and safety of neoadjuvant durvalumab plus novel agents or chemotherapy in resectable NSCLC.